UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2014
Ohr Pharmaceutical, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 333-88480 | | #90-0577933 |
| (State or other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | | |
| 800 Third Avenue, 11th Floor, New York, NY | | 10022 |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (212)-682-8452
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On February 26, 2014, Ohr Pharmaceutical, Inc. (the "Company") entered into a Joint Venture Agreement and related agreements with Cold Spring Harbor Laboratory (“CSHL”) pursuant to which a joint venture,DepYmed Inc. (“DepYmed”), was formed to further pre-clinical and clinical development ofOhr’s Trodusquemine and analogues as PTP1B inhibitors for undisclosed indications. PTP1B isnon-receptor phospho-tyrosine protein phosphatase. There can be no assurance that DepYmed will be able to design and support clinical trials or otherwise determine the efficacy or commercial potential of Trodusquemine for commercial use, or that regulatory authorities will approve final testing or marketing of any pharmaceutical product. DepYmed will be jointly owned and managed by CSHL and the Company, and will license research from CSHL and intellectual property from the Company.
On March 3, 2014, the Company issued a press release regarding the joint venture with CSHL. A copy of a press release is furnished as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized..
| Dated: March 3, 2014 | OHR PHARMACEUTICAL, INC. |
| | |
| | By: | /s/ Irach Taraporewala, |
| | | Dr. Irach Taraporewala, President and CEO
|
